Eric Drape - 16 Feb 2024 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Reporting relationship: Executive VP Global Operations
Issuer ticker: TEVA
Reported as of: 16 Feb 2024
Net transaction value: -$2,261,905
SEC form: 4
Accepted by SEC: 21 Feb 2024, 07:37:43 UTC
Prior SEC filing: 01 Feb 2024
Next SEC filing: 01 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Dov Bergwerk as attorney-in-fact for Eric Drape

Key filing fact

Eric Drape filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 21 Feb 2024.

Key facts

This page summarizes Eric Drape's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 Feb 2024, 07:37.

Change

Previous filing in this sequence was filed on 01 Feb 2024.
Current net transaction value: -$2,261,905.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Ordinary Shares

Sale

Transaction value: $2,261,905
Shares: -173,261
Change %: -100%
Price: $13.05
Shares after: 1
Date: 16 Feb 2024
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.01 to $13.15, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F3

Number of shares rounded to the nearest whole share.